These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 19463252)

  • 1. [Amikacin pharmacokinetics in adults: a variability that question the dose calculation based on weight].
    Bourguignon L; Goutelle S; Gérard C; Guillermet A; Burdin de Saint Martin J; Maire P; Ducher M
    Therapie; 2009; 64(1):47-53. PubMed ID: 19463252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Not Available].
    Bourguignon L; Goutelle S; Gérard C; Guillermet A; de Saint Martin JB; Maire P; Ducher M
    Therapie; 2009; 64(1):47-53. PubMed ID: 27392614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Assessment of pharmacokinetic parameters of amikacin in a group of neutropenic patients in onco-hematology].
    Pivot-Dumarest C; Deweerdt C; Troncy J; Sorensen P; Roux D; Maire P
    Pathol Biol (Paris); 1996 Apr; 44(4):299-305. PubMed ID: 8763595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Calculation of the first dose of amikacine: evaluation of the current dosage recommendations].
    Jean-Bart E; Debeurme G; Ducher M; Bourguignon L
    Ann Pharm Fr; 2013 Jan; 71(1):7-12. PubMed ID: 23348851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients.
    Mar Fernández de Gatta MD; Victoria Calvo M; Ardanuy R; Domínguez-Gil A; Lanao JM; Moreno SR
    J Pharm Pharmacol; 2009 Jun; 61(6):759-66. PubMed ID: 19505366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Individual variability of pharmacokinetic parameters of amikacin in the elderly: retrospective studies].
    Vincent S; Maire PH; Bataillard T; Denjean E; Ducrozet P; Laffont A; Visent C; Jelliffe RW
    Pathol Biol (Paris); 1996 Sep; 44(7):667-74. PubMed ID: 8977923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen.
    Conil JM; Georges B; Breden A; Segonds C; Lavit M; Seguin T; Coley N; Samii K; Chabanon G; Houin G; Saivin S
    Int J Antimicrob Agents; 2006 Sep; 28(3):226-30. PubMed ID: 16908121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn.
    Yang RH; Rong XZ; Hua R; Zhang T
    Burns; 2009 Feb; 35(1):75-9. PubMed ID: 18789586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Higher than recommended amikacin loading doses achieve pharmacokinetic targets without associated toxicity.
    Gálvez R; Luengo C; Cornejo R; Kosche J; Romero C; Tobar E; Illanes V; Llanos O; Castro J
    Int J Antimicrob Agents; 2011 Aug; 38(2):146-51. PubMed ID: 21612894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of three dosage regimens of amikacin using pharmacokinetic models in patients with cystic fibrosis].
    Halacová M; Průsa R; Kotaska K; Vávrová V
    Cas Lek Cesk; 2004; 143(3):187-90. PubMed ID: 15134039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlations between aminoglycoside pharmacokinetic parameters and patient's factors: from statement to implication for individual dosage design.
    Firsov AA; Nasonov VN
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():327-31. PubMed ID: 1820904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing the initial amikacin dosage in adults.
    White BP; Lomaestro B; Pai MP
    Antimicrob Agents Chemother; 2015 Nov; 59(11):7094-6. PubMed ID: 26282426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of population pharmacokinetics with NONMEM in clinical patients treated with amikacin by intravenous infusion].
    Chu XM; Rui JZ; Zhou YG; Dai YJ; Cai WM; Ling SS
    Yao Xue Xue Bao; 1996; 31(12):881-5. PubMed ID: 9863218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empirical models for dosage optimization of four beta-lactams in critically ill septic patients based on therapeutic drug monitoring of amikacin.
    Delattre IK; Musuamba FT; Verbeeck RK; Dugernier T; Spapen H; Laterre PF; Wittebole X; Cumps J; Taccone FS; Vincent JL; Jacobs F; Wallemacq PE
    Clin Biochem; 2010 Apr; 43(6):589-98. PubMed ID: 20036226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetics of amikacin in the subeschar tissue fluid following severe burns].
    Yang RH; Rong XZ; Zhang T; Hua R
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Feb; 27(2):172-4. PubMed ID: 17355928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Interindividual pharmacokinetic variability in long-term antibiotherapy].
    Bourguignon L; Goutelle S; de Saint Martin JB; Guillermet A; Bouniot P; Maire P; Ducher M
    Med Mal Infect; 2010 Jan; 40(1):38-41. PubMed ID: 19346086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacokinetics of amikacin in Greyhound and Beagle dogs.
    KuKanich B; Coetzee JF
    J Vet Pharmacol Ther; 2008 Apr; 31(2):102-7. PubMed ID: 18307501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of high-dose nebulized amikacin in ventilated critically ill patients.
    Petitcollin A; Dequin PF; Darrouzain F; Vecellio L; Boulain T; Garot D; Paintaud G; Ternant D; Ehrmann S
    J Antimicrob Chemother; 2016 Dec; 71(12):3482-3486. PubMed ID: 27516474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amikacin in neonates: dosing recommendations should be based on both pharmacokinetics and dynamics.
    Allegaert K; Sherwin CM
    Singapore Med J; 2010 Jan; 51(1):88-9. PubMed ID: 20200782
    [No Abstract]   [Full Text] [Related]  

  • 20. Determination of Optimal Amikacin Dosing Regimens for Pediatric Patients With Burn Wound Sepsis.
    Yu T; Stockmann C; Healy DP; Olson J; Wead S; Neely AN; Kagan RJ; Spigarelli MG; Sherwin CM
    J Burn Care Res; 2015; 36(4):e244-52. PubMed ID: 25185930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.